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Abstract
Introduction: Psoriasis is a chronic inflammatory skin condition for which there is no cure. Treatment options are designed to control
the disease symptoms and improve patients’ quality of life, and physical and mental function. Established treatments can be effective
but are also limited by tolerability, convenience, cosmetic, and economic issues. Etanercept, a fully human soluble tumor necrosis factor
(TNF) receptor protein, is a recently approved systemic treatment for chronic moderate to severe plaque psoriasis. 
Aim: To evaluate the evidence for the therapeutic value of etanercept in psoriasis. 
Evidence review: There is clear evidence that etanercept 25 mg or 50 mg twice per week reduces physician-assessed severity of
psoriasis and can lead to clearing when compared with placebo. There is substantial evidence that etanercept improves patients’ quality
of life as determined by both disease-specific and generic instruments. Emerging evidence includes improvements in symptoms
associated with depression and fatigue. The tolerability of etanercept in patients with psoriasis appears to be similar to placebo. Initial
indications from clinical trials suggest that there is no increased risk of infection or malignancy in etanercept-treated patients with
psoriasis. The most common adverse events are reversible injection site reactions. Economic evidence is at present limited, although
intermittent etanercept 25 mg is considered cost effective in patients with severe disease unsuitable for systemic treatment. 
Clinical value: Etanercept is an effective and efficient treatment for patients with moderate to severe psoriasis that may be suitable for
intermittent use.
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Core evidence clinical impact summary for etanercept in psoriasis
Outcome measure Evidence Implications
Patient-oriented evidence
Severity and clearance of disease Clear  Etanercept reduces disease severity and improves clearance rates compared 
with placebo
Delay of relapse  Clear Relapse occurs after a mean of 3 months from cessation of active treatment, 
with relapse >4.5 months in 20% of patients
Quality of life  Clear Etanercept improves quality of life measures more than placebo
Tolerability  Substantial Injection site reactions are more common with etanercept compared with placebo.
Screening procedures and guidelines should be used when considering patients for
treatment in order to reduce the risk of serious infection and to monitor the potential
risk of malignancy
Economic evidence
Cost effectiveness Moderate Etanercept 25 mg twice weekly is cost effective in patients with severe disease 
who are not suitable for systemic therapyScope, aims, and objectives
Psoriasis is a chronic condition of the skin affecting a significant
proportion of the population that can lead to profound effects 
on quality of life and both physical and mental function. 
The condition can range in severity from the presence of a few
localized lesions to more widespread disease affecting most of
the body area, including the scalp, palms, soles of the feet, face,
genitals, and nails. There is no cure for the disease, and the
primary treatment goals are control of lesions and improvements
in patients’ quality of life. 
Although mild forms of the disease may be managed effectively
with existing topical therapies, established systemic or
phototherapy may be required to treat moderate to severe
disease. However, long-term treatment with traditional
systemics and phototherapy may be associated with significant
adverse events, not all patients are responsive, and many
treatments are reimbursed at low rates. Therefore, there is a
need for effective, well-tolerated, and conveniently administered
treatments for the management of psoriasis. In 2004, etanercept
(Enbrel®; Amgen and Wyeth Pharmaceuticals) was the first
tumor necrosis factor (TNF) receptor approved for the treatment
of moderate to severe psoriasis. Although also approved for
psoriatic arthritis (which occurs in approximately 40% of
patients with extensive disease) the objective of this article is to
review the clinical evidence base for the use of etanercept
specifically for psoriasis. 
Methods
The English language medical literature was searched in March
2006 in the following databases. The search strategy was
“etanercept AND psoriasis” for articles published from January
1990 to November 2005 (inclusive). Nonhuman and in-vitro
studies were excluded from the search. 
• PubMed, http://www.ncbi.nlm.nih.gov/entrez/query.fgci
• EMBASE, http://www.datastarweb.com
• BIOSIS, http://www.datastarweb.com
• Database of Abstracts of Reviews of Effects (DARE),
http://www.york.ac.uk/inst/crd/crddatabases.htm
• Cochrane Database of Systematic Reviews (CDSR),
http://www.cochrane.org/index.htm
• Clinical Evidence (BMJ), http://www.clinicalevidence.com
• National Institute for Health and Clinical Excellence (NICE),
http://www.nice.org.uk
• National Guideline Clearinghouse, http://www.guideline.gov
• Clinical trial register http://www.clinicaltrials.gov
A total of 35 publications (excluding guidelines) were identified
from the search strategy (Table 1). Studies concerned exclusively
with palmoplantar pustular psoriasis, guttate psoriasis, or
psoriatic arthritis were excluded. Following the search and
manual checking of the references, 13 full papers and 12 meeting
abstracts (from PubMed, BIOSIS, and EMBASE) were included in
the evidence base. The search was repeated on September 22,
2006, yielding another five papers, and two more studies were
identified, resulting in a total of 30 records in the evidence base. 
Disease overview
Psoriasis is a chronic inflammatory skin condition that affects
about 2% of the population (Pardasani et al. 2000). It is a disease
that interferes with many normal daily activities, including use of
the hands, walking, sleeping, and sexual activity. In fact, psoriasis
has been reported to cause greater physical and mental distress
compared with many other major diseases, including arthritis,
chronic lung disease, chronic heart failure, and diabetes 
(Rapp et al. 1999). As such, it has a profound emotional and social
as well as physical impact on quality of life (Krueger et al. 2001).
There are several types of psoriasis with plaque-type being the
most common form, accounting for over 80% of cases. Guttate
psoriasis occurs in about 10% of patients, and erythodermic and
pustular types each occur in fewer than 3% of patients 
(Lebwohl 2003). Plaque psoriasis is characterized by sharply
demarcated, erythematous, scaling plaques, typically affecting
the elbows, knees, scalp, and intergluteal cleft. In some patients,
lesions may appear on the palms and soles before other areas are
affected, and lesions may occasionally appear on the genitals,
face, and nails (Lebwohl 2003). 
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Category Number of records
Full papers Abstracts
Initial search 16 19
records excluded 5 7
records included 11 12
Additional papers identified 2 0
Search update, new records 111 0
records excluded 106 0
records included 5 0
Level 1 clinical evidence 1 5
Level 2 clinical evidence 7 4
Level ≥3 clinical evidence 5 1
trials other than RCT 3 1
case studies 2 0
Economic evidence 0 1
Total records included  18 12
For definition of levels of evidence, see Editorial Information on inside back cover.
RCT, randomized controlled trial.
Table 1 | Evidence base included in the review53
Psoriasis leads to considerable economic burden by affecting
direct cost of care and also indirect cost of reduced productivity
in both work and home environments. Visits to US physicians
made by patients principally for care of psoriasis average 
1.5 million visits per year (Stern 1996). A recent estimate of 
the direct costs of care for psoriasis (including psoriatic 
arthritis) in the USA determined the total cost to be 
$US649.6 million for about 1.4 million individuals with clinically
significant disease ($US464 per patient) (Javitz et al. 2002). 
This estimate is likely to increase given the higher acquisition
costs of newer biologic therapies that are now available for the
treatment of psoriasis. 
Recent investigations into the pathogenesis of psoriasis have led
to the recognition of the importance that the immune system
plays in the disease. This in turn has led to the development of
biologic therapies that target cells and mediators that are
implicated in inflammatory aspects of the disease. 
Current therapy options
As there is no definitive cure for psoriasis, the goals of treatment
include long-term improvement in the physical signs and
secondary functional and psychologic effects, reduction in
inflammation, and control of skin shedding. Improvement in
patients’ quality of life is also important given the serious impact
the disease has on physical, mental, emotional, and social
functioning (Krueger et al. 2001). 
There are a number of established therapeutic options available
which range from topical treatments for mild disease to systemic
or phototherapy for more severe disease (Lebwohl 2003). 
The most commonly prescribed treatments for psoriasis in the
USA and many other parts of the world are topical corticosteroids
which are available in a number of strengths and forms 
(e.g. creams, sprays, gels). Other topical treatments include coal
tar preparations, vitamin D analogs, and tazarotene (a retinoid 
and the most recent development in topical therapy) (Table 2). 
Phototherapy or systemic therapy is used in patients whose
psoriasis is not controlled adequately with topical treatments or
whose disease is too widespread. Phototherapy options include
ultraviolet B (UVB) light or the combination of oral psoralen
followed by irradiaton with UVA light (PUVA). Established
systemic treatments include methotrexate, cyclosporin, and
acitretin. The beneficial effects achieved with these drugs have
led to the introduction of more selective agents following detailed
investigations into the pathogenesis of psoriasis. Thus, targeted
therapies that interfere with immunologic steps in the
pathogenesis of the disease, such as inhibitors of T-cell activation
and inhibitors of specific cytokines, have been developed. 
One such agent is etanercept, which blocks the action of TNF, 
an inflammatory cytokine that plays an important role in psoriasis
(Bonifati & Ameglio 1999). 
Outcomes to determine effectiveness in psoriasis include both
clinical and patient-reported measures. The Psoriasis Area and
Severity Index (PASI) is an outcome measure commonly used by
physicians in clinical studies (Ashcroft et al. 1999). It is a
composite index indicating the severity of the three main
characteristics of psoriatic plaques (erythema, scaling, and
thickness, scored 0–4 for each), weighted by the amount 
of coverage (on a scale of 0–6) on the four main body areas 
(head, arms, legs, and trunk). The index ranges from 0 
(no psoriasis) to 72 (most severe disease). Improvements in PASI
of 50, 75, and 90% (PASI 50, 75, and 90, respectively) are often
used as clinical outcomes.
Although PASI may be a popular measure in clinical studies, 
it is not often applicable to general dermatology practice. 
The Physician’s Global Assessment (PGA) is more widely used 
in clinical practice (Jacob et al. 2005). This instrument corresponds
to the physician’s global assessment of changes in all psoriatic
lesions compared to the baseline condition and is often helped by
referral to photographs taken before treatment begins. It is
common for the PGA to be reported on a scale of 0 to 5 
(0 indicating no disease or clear of psoriasis, with higher 
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Classification Treatment  Risks and comments 
Localized or topical treatments Topical corticosteroids, various potencies Skin atrophy; rebound may occur on withdrawal
Vitamin D analogs Skin atrophy
Coal tars Strong smell and staining; may cause folliculitis
Anthralin Staining; irritation to normal tissue
Tazarotene  Increased phototsensitivity; avoid use in women of childbearing potential
Generalized or systemic treatments  UVB phototherapy Acute phototoxicity
PUVA Acute phototoxicity and cutaneous malignancy 
Retinoids (acitretin) Teratogenic; avoid use in women of childbearing potential
Methotrexate Hepatotoxicity; acute neutropenia and pancytopenia
Cyclosporine Renal toxicity
PUVA, oral psoralen and irradiation with ultraviolet A light; UVB, ultraviolet B light. 
Table 2 | Established treatment options for psoriasisscores indicating more severe disease). Worsening of disease 
can be denoted by a value of –1 (Shikiar et al. 2003). Both the
PASI and PGA are highly correlated (r>0.8) and have high overall
reliability (r>0.9) (Langley & Ellis 2004). 
Because of the marked negative influence that psoriasis can 
have on patients’ quality of life, it is important to determine
patient-reported outcomes. Examples of these measures include
disease-specific measures, such as the Psoriasis Symptom
Assessment (PSA) scale, Patient’s Global Assessment of
Psoriasis, the Dermatology Life Quality Index (DLQI), and generic
instruments such as the Short Form-36 Health Survey (SF-36).
The DLQI contains ten items relating to the patient’s skin with 
a score range of 0 to 30 (higher scores indicating poor quality 
of life) and can be self-administered. The instrument contains six
subscales: daily activities, symptoms and feelings, work/school,
leisure, personal relationships, and treatment satisfaction 
(Shikiar et al. 2003). 
In order to determine disease severity, it is necessary to assess the
sum of the effect of the signs and symptoms of psoriasis and the
impact that it has on the patient’s life. It is possible to define severe
disease as a PASI score of >10 (or an involvement of >10% of the
body surface area involved) and a DLQI score of >10 (Finlay 2005). 
Unmet needs
Despite the availability of many treatments for psoriasis, their
adverse effects or inadequate efficacy have created the need for
more effective, and better tolerated therapies (Lebwohl 2003).
For example, in a survey of 6194 patients with severe psoriasis
conducted in 1998, 40% felt frustrated with the ineffectiveness of
their current treatment and 32% reported that treatment was not
aggressive enough (Krueger et al. 2001). A more recent survey of
4.5 million adults in the USA indicated that over 22% of patients
with psoriasis had substantial dissatisfaction with their treatment
(Stern et al. 2004). This may be due in part to serious risks or
other factors being associated with a number of established
treatments (Table 2). 
Topical treatments require lengthy (at least overnight) skin exposure
and can be inconvenient and awkward to apply, especially if 
a large PSA is affected. Tars are messy and stain the skin, 
and few patients can tolerate the smell. Attempts to produce effective
nonstaining preparations that are not greasy have been
unsuccessful. Lengthy use of topical corticosteroids can also lead 
to skin atrophy, systemic toxicity, and tachyphylaxis or flare-up in
disease after discontinuation. PUVA is a very effective treatment but
is associated with the risk of developing cutaneous malignancy.
Several highly effective systemic treatments are available, but they
are also associated with a number of adverse side effects. 
For example, acute neutropenia and chronic hepatotoxicity can
occur with methotrexate, and long-term use of cyclosporin is
associated with nephrotoxicity (Pardasani et al. 2000; Lebwohl 2003). 
Therefore, there is still the need for effective, well-tolerated, and
convenient options for treating psoriasis. One type of treatment
that may address these requirements is biologic targeted 
therapy. Etanercept is a recombinant human TNF-receptor fusion
protein which inhibits the interaction of endogenous TNF with
cell-surface receptors. It was first approved for the treatment of
psoriatic arthritis by the US Food and Drug Administration (FDA)
in January 2002. This was followed in May 2004 with approval
from the FDA for the treatment of moderate to severe plaque
psoriasis in patients who are candidates for systemic therapy or
phototherapy. In September 2004, approval was gained in the
European Union for etanercept to be used for the treatment of
adult patients with moderate to severe plaque psoriasis who
failed to respond to, have a contraindication to, or are intolerant
of other systemic therapies. 
Clinical evidence with etanercept in psoriasis
Clinical outcomes
There is clear evidence that treatment with etanercept can
achieve rapid, significant improvements in the activity and
severity of psoriasis as assessed by physicians. 
Improvement in PASI
Encouraging results in PASI obtained in a phase II trial with
etanercept in 60 patients with psoriatic arthritis have been
confirmed in a meta analysis which evaluated data from one phase
II (Gottlieb et al. 2003) and two phase III randomized controlled
studies (Leonardi et al. 2003; Papp et al. 2005) with etanercept
specifically in patients with psoriasis. However, this analysis has
only been published in abstract form (Gordon et al. 2004; van der
Kerkhof et al. 2004a), making full evaluation difficult. The inclusion
criteria for the studies were almost identical: patients (n=1187) with
stable chronic plaque psoriasis involving at least 10% body
surface area who had received (or were candidates for) photo- or
systemic therapy. In this analysis, a significantly higher proportion
of etanercept-treated patients (33 and 49% treated with 25 mg
and 50 mg twice weekly, respectively) achieved the primary
endpoint of ≥75% improvement in PASI at 12 weeks compared
with placebo (P<0.0001). In addition, a higher proportion of
patients achieved clearing of disease (≥90% improvement in PASI)
after 12 weeks with etanercept 50 mg twice weekly compared with
placebo (21 vs 1%). The effects of etanercept on improvements in
PASI are also seen in each of the constituent studies of this
analysis (Table 3). 
Results from a further randomized controlled trial of etanercept 
50 mg twice weekly has also confirmed that etanercept improves
PASI scores (Tyring et al 2006). PASI 75 was achieved in 47% of
etanercept recipients compared with 5% of those receiving
placebo, and PASI 90 by 21% and 1%, respectively (P<0.0001 for
both endpoints). A once-weekly dose of etanercept 100 mg has
been shown to be as effective as 50 mg twice weekly, with PASI
50 achieved in 78% of 51 and 74% of 50 patients, respectively,
after 12 weeks (Cassano et al. 2006).
Etanercept efficacy was also maintained after reducing the dose
in an open-label extension of a phase III study (Papp et al. 2005).
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After 12 weeks of double-blind treatment with etanercept 50 mg
twice weekly, patients (n=179) were switched to 25 mg twice
weekly, and PASI 75 response at weeks 12 and 24 were
compared. Most (70/91; 77%) of the PASI 75 responders at week
12 maintained their response at week 24. Of those 21 patients
who did not maintain PASI 75 by week 24, three failed to maintain
a PASI 50 response. At week 12, 88 patients had not achieved a
PASI 75 response, however, by week 24, 32% of the 88 patients
had done so despite the decrease in etanercept dose. A similar
pattern emerged in patients initially not achieving PASI 50 in 
an open-label study (Kreuger et al. 2006). Forty-three percent of 
157 patients failing to achieve PASI 50 after 24 weeks of
treatment with etanercept 50 mg/week subsequently did so 
after 36 weeks, increasing to 55% after 60 weeks. 
Onset of action 
There is evidence that etanercept achieves efficacy within 2 to
4 weeks of starting treatment (Leonardi et al. 2003). Differences in
the numbers of patients considered clear/almost clear of
psoriasis and mean improvements in PASI with etanercept
compared with placebo were evident within this time. PASI scores
were improved significantly after 4 weeks of high-dose (50 mg
twice weekly) and 8 weeks of medium-dose (25 mg twice weekly)
treatment compared with placebo. The proportion of patients
assessed as being clear or almost clear of psoriasis was
significantly different for all the etanercept groups by week 4
compared with the placebo group. 
Relapse
In the study by Leonardi et al. (2003), patients classified as
responders (≥PASI 50 from baseline) were discontinued 
from treatment after 24 weeks and followed until their disease
relapsed (loss of ≥50% of PASI improvement) (Gordon et al. 2006).
Of 409 patients entering the withdrawal and retreatment period, 
347 relapsed and received at least one further dose of etanercept,
and 297 completed 12 weeks of retreatment. The median time to
relapse was 85 days, with 25% of the responders not relapsing until
after 145 days (Gottlieb et al. 2004c; Leonardi et al. 2004). In a
subset of 252 patients who achieved PASI 75 after 24 weeks,
median time to loss of this response was 57 days, and loss of PASI
50 occurred in a median of 91 days (Gordon et al. 2006). During the
withdrawal period only one patient returned to >125% of baseline
PASI score. No cases of conversion of psoriasis morphology were
seen. After 12 weeks, the overall effect of etanercept retreatment
(mean PASI score 6.4) was similar to the initial treatment effect
(mean PASI score 5.8), and 83% of patients achieving PASI 50
during initial treatment achieved the same response after 12 weeks
of retreatment. Although from only one cycle of discontinuation and
retreatment, these results suggest that etanercept may be used
effectively in an intermittent or rotational approach to treat psoriasis. 
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Level of evidence Reference Design  Treatment (mg) Patients achieving PASI ≥75 at 12 weeks (%)
1a Gordon et al. 2004;
van der Kerkhof et al.
2004a
R, DB, PC, 12-week study involving 
1187 patients
ETN 25 biw
ETN 50 mg biw
PLA
33
49
3 (P<0.0001 vs ETN)
1a Strober et al. 2004 R, DB, PC, 12-week study involving 
415 patients ± previous systemic or
phototherapyb
ETN 25 biw 33 vs 34 (NS) for patients ±  previous systemic
or phototherapy, respectively
2 Mease et al. 2000 R, DB, PC, 12-week study involving 
38 patients (psoriasis ≥3% BSA involvement)
ETN 25 biw
PLA
26
0 (P=0.0154 vs ETN)
2 Gottlieb et al. 2003 R, DB, MC, PC 24-week study involving 
112 patients
ETN 25 biw
PLA
30
2 (P<0.0001 vs ETN)
2 Leonardi et al. 2003 R, DB, PC, 24-week study involving 
672 patients
ETN 25 qw
ETN 25 biw
ETN 50 biw
PLA
14
34
49
4 (P<0.0001 vs ETN)
2 Papp et al. 2005 R, DB, PC, 24-week (OL phase during 
weeks 13–24) study involving 583 patients
ETN 25 biw
ETN 50 biw
PLA
34
49
3 (P<0.0001 vs ETN)
2 Tyring et al. 2006 R, DB, MC, PC, 12-week study involving 
618 patients followed by an 84-week, 
OL, active treatment period
ETN 50 biw
PLA
47
5 (P<0.0001 vs ETN)
2 Cassano et al. 2006 R, DB, 12-week study involving 
101 patients
ETN 50 biw
ETN 100 qw
54
50
aAbstract.
bSubanalysis of Gordon et al. 2004 and van der Kerkhof et al. 2004a.
biw, twice weekly; BSA, body surface area; DB, double-blind; ETN, etanercept; MC, multicenter; NS, nonsignificant; OL, open-label; PASI, Psoriasis Area and Severity Index; PC, 
placebo-controlled; PLA, placebo; qw, once weekly; R, randomized.
Table 3 | Effect of etanercept on Psoriasis Area and Severity Index (PASI) score in patients with psoriasis Previously treated patients
Results from the meta analysis showed that etanercept was as
effective in patients with severe disease who had been treated
previously with systemic or phototherapy as in those with no such
history (Strober et al. 2004; Table 3). In 415 patients randomized
to etanercept 25 mg twice weekly, those with a history of
systemic or phototherapy had significantly (P>0.01) more severe
disease (body surface area involvement 30 vs 21%) of longer
duration (21 vs 17 years), and higher baseline PASI score 
(19.2 vs 16.0), compared with those with no history (P>0.01 for all
parameters). Despite these differences, the same proportions 
of patients in both groups achieved comparable PASI responses
after 12 and 24 weeks of treatment (Table 3). 
Quality of life 
There is good evidence from randomized controlled trials that
etanercept rapidly improves patient-reported disease and quality
of life outcomes in psoriasis (Table 5). 
A meta analysis of quality of life outcomes has been carried out
following analysis of data from one phase II (Nayak & Zitnik 2003;
Gottlieb et al. 2004a) and two phase III randomized controlled
studies (Leonardi et al. 2003; Papp et al. 2005) with etanercept.
Results from this meta analysis have appeared as abstracts 
from meetings (Gordon et al. 2004; Singh et al. 2004; van der
Kerkhof et al. 2004b). 
The meta analysis showed that after 12 weeks of treatment the
odds of achieving a clinically meaningful improvement in DLQI
total score (defined as 5 points) were four to five times higher with
either etanercept 25 mg or 50 mg twice weekly compared with
placebo (P<0.0001) (Singh et al. 2004). This is a reflection of the
mean percentage improvement from baseline of 51.5 and 59.1%
in DLQI scores with etanercept 25 mg and 50 mg twice weekly,
respectively, compared with placebo treatment (Singh et al. 2004;
van der Kerkhof 2004b). In addition, treatment with both doses of
etanercept resulted in statistically significant improvements in
each of the six subscales of the DLQI compared with placebo. 
Improvements in DLQI were also achieved irrespective of whether
patients had a history of previous treatment with systemic or
phototherapy (Strober et al. 2004). As well as having more severe
disease, patients with a history of previous systemic therapy also
had a worse DLQI score at baseline compared with those who did
not (11.9 vs 10.4, P<0.01). Yet after treatment with etanercept 
25 mg twice weekly, the improvements in DLQI after 12 (60 vs
54%) and 24 weeks (64 vs 61%) were not significantly different in
previously treated or untreated patients.
Details of significant etanercept-related improvements in both
disease-specific (DLQI) and generic (SF-36) quality of life
measures from one of the constituent studies of the meta analysis
have been reported recently (Krueger et al. 2005; Table 5). In this
study etanercept produced improvements in patient-reported
outcomes as early as 2 weeks after starting therapy. Compared
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Level of evidence Reference Design  Treatment Outcomes
2a Nayak & Zitnik 2003;
Gottlieb et al. 2004a
R, DB, MC, PC, 24-week
study involving 31
patientsb
ETN 25 mg or 50 mg
biw, or PLA
Skin biopsy samples taken from patients showed that 
clinical efficacy with ETN was associated with reductions 
in several markers of inflammation, including epidermal
thickness, epidermal T-cell infiltration, and keratinocyte
activation and proliferation 
2 Mease et al 2000 R, DB, PC, 12-week study
involving 38 patients
(psoriasis ≥3% BSA
involvement)
ETN 25 mg biw, or
PLA
Median response of target lesion: 50% with ETN vs 0% 
with PLA (P=0.0004)
3 Jacob et al. 2005 CS, chart review of 53
patients treated with ETN
ETN in patients for
whom traditional
systemic treatments
had failed to control
psoriasis
50% of patients achieved PGA ≥3, 73.5% patients
discontinued or decreased previous systemic therapies, 
and maintained their PGA score with ETN
3a Elewski et al. 2005 OL extension of phase III
studies 
ETN 25 mg biw
switched to 50 mg qw
for 12 weeks in OL
extension
• Mean PASI score at start of OL (5.77) was maintained 
by switch to ETN 50 mg (5.82, P=0.76)
• A similar proportion of patients achieved DGA
“clear/almost clear” status with ETN 25 mg (43%) 
vs ETN 50 mg (38%)
• Comparable pharmacokinetic profile for both 
dosing regimens
aAbstract.
bSubstudy of Gottlieb et al. 2003.
cLeonardi et al. 2003 and Papp et al. 2005.
biw, twice weekly; BSA, body surface area; CS, cohort study; DB, double-blind; DGA, Dermatologist Global Assessment of psoriasis; ETN, etanercept; MC, multicenter; OL, open-label; 
PASI, Psoriasis Area and Severity Index; PC, placebo-controlled; PGA, Physician’s static Global Assessment of psoriasis; PLA, placebo; R, randomized; qw, once weekly.
Table 4 | Effect of etanercept on other disease-related outcomes in patients with psoriasis57
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with placebo-treated patients, a significantly greater proportion of
etanercept-treated patients reported clinically important
improvements (≥5 points, or a score of 0) in DLQI scores at week
12 (P<0.0001). In all six DLQI subscales, improvements in patients
treated with etanercept were significantly greater than in those
treated with placebo. The two subscales showing the greatest
levels of improvement with etanercept were the symptoms and
feelings and daily activities subscales (P<0.0001). 
Significant improvements in patients’ functional status were also
seen with SF-36 scores after 12 weeks of etanercept treatment.
Both the physical and mental component scores were
significantly higher in patients treated with etanercept compared
with placebo-treated patients (P<0.01). In addition, all eight
subscales were improved significantly with etanercept compared
with placebo; the greatest mean changes occurred in the
measures of bodily pain (P<0.0001) and social function subscales
(P<0.001). During the open-label phase of the study, patients who
had originally received etanercept 50 mg twice weekly maintained
the improvement in patient-reported outcomes when switched 
to etanercept 25 mg twice weekly.
In addition to improvements in DLQI, evidence is emerging that
etanercept treatment may improve symptoms of depression and
fatigue in patients with psoriasis (Tyring et al. 2006). In this study,
depression was assessed by both the Beck Depression Inventory
(BDI; patient-administered questionnaire) and the Hamilton rating
scale for depression (Ham-D; administered by trained healthcare
professionals). Although depression is reported to be a common
finding in patients with psoriasis, it is notable in this study
involving 618 patients that at baseline only a few patients in the
etanercept and placebo groups had moderate to severe
depression; 15 and 16%, respectively, as determined by the BDI
and 2% in each group as determined by the Ham-D. This may be
due, in part, to strict study inclusion criteria discouraging the 
most depressed participants from enrollment (Tyring et al. 2006). 
At baseline, most patients had no (74%, Ham-D score) or minimal
(66%, BDI scale) depression. Nevertheless, results from the study
showed that more patients treated with etanercept achieved at
least a 50% improvement in both of these scales after 12 weeks
compared with placebo. Significant improvement in the BDI total
score was achieved after 4 weeks of treatment with etanercept
compared with placebo (P=0.0062). 
Patients with psoriasis in this study were also more fatigued
compared with historic data for the general population (mean
baseline functional assessment of chronic illness therapy—
fatigue [FACIT-F] score 3.78±11.2 vs 43.6±9.4 for the general
population). After only 2 weeks of treatment with etanercept,
patients showed a significantly greater improvement in FACIT-F
score compared with placebo-treated patients (P=0.0048). After
12 weeks of treatment, the mean improvement in score of 5.0
points for etanercept-treated patients was significant and
clinically meaningful compared with placebo (1.9 points,
P<0.0001). Therefore, given the limitations of the baseline
characteristics of the study population, the data suggest that
there is limited evidence that etanercept treatment improves
symptoms of depression and fatigue in patients with psoriasis. 
Other outcomes
Statistically significant improvements in patient global, physician
global, and target lesion assessments were reported to have been
achieved with etanercept although results from these trials were
available as abstracts only, and specific data were missing 
(Nayak & Zitnik 2003; Gottlieb et al. 2004a). However, results from
skin biopsy samples taken from a subset of patients (17 treated
with etanercept, 14 treated with placebo) showed that markers of
inflammation and other endpoints were reduced with etanercept
compared with placebo treatment. For example, the mean
reduction in epidermal thickness after 12 weeks of treatment was
greater with etanercept (44%) compared with placebo 
(7%, P<0.05). (Gottlieb et al. 2004a). There were also reductions
in keratinocyte adhesion protein expression (keratinocyte 
ICAM-1), and epidermal T-cell (CD3) infiltration and proliferation
(epidermal Ki 67) associated with etanercept treatment (Table 4). 
Improvement in psoriatic skin lesions with etanercept was also
seen in the study by Mease et al. (2000). The median response of
a prospectively defined target lesion in the etanercept group was
50% compared with 0% in the placebo group (P=0.0004) 
(Table 4). In addition, a chart review of 53 patients showed that
treatment with etanercept also led to discontinuation or dose
reduction in previous systemic therapies in nearly three-quarters
of patients while maintaining their PGA score (Jacob et al. 2005). 
Tolerability and safety
Reports of the tolerability of etanercept in patients with psoriasis
have been limited to results from clinical trials, and long-term
surveillance data have yet to appear in this population. In clinical
studies involving patients with psoriasis, the incidence of adverse
effects and infections with etanercept have generally been similar
to placebo (Table 6). 
Because of the mode of action, concerns have been raised
regarding the potential for immunosuppression with TNF inhibitors
(including etanercept), leading to infection (notably tuberculosis),
malignancy, and other serious potential toxicities (Hochberg et al.
2005; Smith et al. 2005). Most of the data on the safety of etanercept
have been generated from clinical studies and postmarketing
surveillance in patients with rheumatoid arthritis, and in March 2003
the FDA Arthritis Advisory Committee (AAC) convened for an update
on the safety of TNF inhibitors, including etanercept (ACR 2003a,b).
The meeting focused specifically on the issue of neoplasia and
lymphoma in patients with rheumatoid arthritis. As of the fourth
quarter of 2002, 150 000 patients had been treated with etanercept,
providing 230 000 patient-years of exposure and 70 reports of
lymphoma. This incidence of lymphoma of 0.03 cases per 100
patient-years of exposure is equal to the normal population rate
(ACR 2003a). However, patients with severe psoriasis have an
increased risk (approaching that for patients with organ transplants)
for lymphoproliferative disorders and should, therefore, be followed
for any signs of malignancy irrespective of therapy. 
Only 10% of cases associated with etanercept use, but nearly half
(48%) of all reported cases of tuberculosis, were reported from
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Level of evidence Reference Design  Treatment Outcomes
1a Singh et al. 2004; 
van der Kerkhof et al.
2004b 
R, DB, PC, 12-week study
involving 1187 patients
ETN 25 mg, 50 mg biw,
or PLA 
OR for achieving a clinically meaningful improvement on DLQI:
• 4.20 (95% CI 3.14, 5.63) and 5.87 (95% CI 4.25, 8.10) for
ETN 25 mg and 50 mg, respectively, vs PLA (P<0.0001) 
Mean improvement in DLQI at 12 weeks:
• 51% (95% CI 44.6, 58.1) and 59.1% (95% CI 51.6, 66.6) for
ETN 25 mg and 50 mg, respectively, vs PLA (P<0.0001)
1a Strober et al. 2004 R, DB, PC, 12-week study
involving 415 patients ±
previous systemic or
phototherapyb
ETN 25 mg biw Percentage improvement in DLQI:
• 60 vs 54% (NS) for patients and without previous systemic
or phototherapy at 12 weeks
• 64 vs 61% (NS) for patients and without previous systemic
or phototherapy at 24 weeks
2 Leonardi et al. 2003 R, DB, PC, 24-week study
involving 672 patients
ETN 25 mg qw (low
dose), 25 mg biw
(medium dose), 50 mg
biw (high dose), or 
PLA for 12 weeks 
Percentage improvement in DLQI:
• 47.2, 50.8, and 61.0% in low-, medium-, and high-dose
groups vs 10.9% for PLA (P<0.0001) at 12 weeks
• 54.0, 59.4, and 73.8% in low-, medium-, and high-dose
groups 
PtGA scores improved significantly in all ETN groups 
vs PLA (P<0.001)
2 Krueger et al. 2005 R, DB, PC, 24-week study
(OL phase during 
weeks 13–24) involving
583 patients
ETN 25 mg or 50 mg
biw, or PLA for 
12 weeks
All patients received
ETN 25 mg biw during
OL phase
DLQI at 12 weeks:
• Total score improved by 65–70% for ETN vs 6% for 
PLA (P<0.0001) 
• Clinically meaningful improvements in DLQI achieved by
72–77% for ETN vs 26% for PLA (P<0.0001)
• All 6 subscales were significantly improved by ETN more
than PLA; greatest effects on symptoms and feelings 
(ETN 60–62% vs PLA 6%; P<0.0001), and daily activities
subscale (ETN 56–62% vs 1% PLA; P<0.0001)
SF-36 at 12 weeks
• Mean physical component score was 52.7–52.8 for ETN 
vs 49.6 for PLA (P<0.01)
• Mean mental component score was 50.6–51.0 for ETN 
vs 46.5 for PLA (P<0.01)
• All 8 subscales were significantly improved by ETN more
than PLA; greatest effects on bodily pain (ETN 6.2–7.1 
vs PLA 1.1; P<0.0001), and social function (ETN 3.9–6.0 
vs PLA 0.5; P<0.0001)
2 Tyring et al. 2006 R, DB, MC, PC, 12-week
study involving 618
patients followed by 
an 84-week OL active
treatment period
ETN 50 mg biw, 
or PLA
Improvements in DLQI at 12 weeks:
• 69.1% with ETN vs 22.1% with PLA (P<0.0001)
Depression assessed at 12 weeks:
• Mean difference in improvement in BDI between ETN 
and PLA was 1.8 (95% CI: 0.6, 2.9) (P<0.0001)
• Mean difference in improvement in Ham-D between ETN
and PLA was 1.2 (95% CI: 0.4, 1.9) (P<0.0001)
Fatigue assessed at 12 weeks:
• Mean difference in improvement in FACIT-F between ETN
and PLA was 3.0 (95% CI: 1.6, 4.5) (P<0.0001)
2 Cassano et al. 2006 R, DB, 12-week study
involving 101 patients
ETN 50 biw
ETN 100 qw
Mean improvement in DLQI: 68%
Mean improvement in DLQI: 66%
3a Elewski et al. 2005 12-week OL extension of
ETN phase III studies
involving 265 patients 
ETN 25 mg biw
switched to 50 mg qw
for 12 weeks in OL
extension
Mean DLQI score at start of OL (3.13) was maintained 
by switch to ETN 50 mg (3.03)
aAbstract.
bSubanalysis of Singh et al. 2004 and van der Kerkhof et al. 2004a.
BDI, Beck Depression Inventory; biw, twice weekly; CI, confidence interval; DB, double-blind; DLQI, Dermatology Life Quality Index; ETN, etanercept; FACIT-F, functional assessment of chronic
illness therapy—fatigue; Ham-D, Hamilton rating scale for depression; NS, nonsignificant; OL, open-label; OR, odds ratio; PC, placebo-controlled; PLA, placebo; PtGA, Patient’s Global
Assessment of psoriasis; R, randomized; SF-36, Short Form-36 Health Survey; qw, once weekly.
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outside the USA where the endemic rate of the disease is greater
(ACR 2003b). Simple screening procedures can be used to limit
the risk of opportunistic infections, particularly tuberculosis, in
new patients (ACR 2003b). Any patient who develops a new
infection while undergoing treatment with etanercept should be
monitored closely and treatment discontinued if the patient
develops a serious infection or sepsis (Anon. 2006). There have
been rare cases of new onset or exacerbations of existing
demyelinating disorders following the use of TNF inhibitors. For
example, 17 patients with rheumatoid arthritis developed
neurologic events identified from the Adverse Events Reporting
System FDA database. All these events were temporally related to
TNF inhibitor therapy, but these resolved (partially or completely)
after discontinuing the drug (Mohan et al. 2001). Therefore,
prescribers should exercise caution when considering using
etanercept in patients with preexisting or recent-onset central
nervous system demyelinating disorders (Anon. 2006). 
A meta analysis of three randomized controlled studies with
etanercept in patients with psoriasis showed that no new or
unanticipated patterns of adverse events occurred during the 12-
week treatment period (Gottlieb et al. 2004b, 2006). This analysis
included 1347 patients with psoriasis, 1261 of whom received at
least one dose of etanercept (25 mg once or twice weekly, or 
50 mg twice weekly) for a total of 933 patient-years of exposure.
Discontinuation due to adverse events was similar in the pooled
etanercept group (1.8%) compared with placebo (2.0%) after 
12 weeks of treatment, and serious adverse events were
experienced by similar proportions of patients in both groups
(1.7% etanercept vs 1.2% placebo). Rates of serious infections
requiring hospitalization were low (0.3% etanercept vs 1.2%
placebo) in both groups, and no opportunistic infections or cases
of tuberculosis were reported. In addition, the safety profile of
etanercept 50 mg twice weekly in patients with psoriasis was
comparable to that of patients treated with 25 mg twice weekly
(the approved regimen for patients with rheumatoid arthritis).
Thus, over 12 weeks of treatment, the safety profile seen with
etanercept in patients with psoriasis was comparable to that of
placebo and was consistent with experiences in populations with
rheumatoid arthritis (Gottlieb et al. 2004b, 2006). 
Economic evidence
The economic evidence for the use of etanercept in psoriasis is
limited to the models summarized in the NICE technology appraisal
(NICE 2006), a paper from a US managed care perspective
(Simpson et al. 2006), and an abstract (Nallamothu et al. 2004). 
The NICE technology appraisal reports a model from the
manufacturer of etanercept, and their own. The manufacturer’s
model was a Markov model using pooled data from three RCTs to
evaluate the cost effectiveness of etanercept 25 mg or 50 mg twice
weekly and topical therapy only. Quality-adjusted life-year (QALY)
gain was estimated from improvements in DLQI between physician
assessments over a 12-week period and eight further 12-week
periods. The incremental cost-effectiveness ratio (ICER) for
etanercept 25 mg compared with topical therapy was £125 000 per
QALY over 12 weeks, and £37 200 for intermittent therapy over 96
weeks. The ICER decreased to £24 000 in patients with severe
psoriasis and poor quality of life (PASI >10, DLQI >15). The NICE
Technology Assessment Group model estimated QALY by mapping
changes in DLQI to a nonspecific health-related quality of life
instrument, EQ-5D. An intermittent regimen was assumed to be 3.2
12-week treatment cycles each year with 29-day intervals between
cycles. The ICER for intermittent etanercept 25 mg was £65 320 per
QALY, decreasing to £14 460 if the scenario included poor quality
of life and hospitalization for nonresponders, defined as patients
with PASI ≥10 and DLQI >10 unresponsive to systemic therapy.
Etanercept was more cost effective than efalizumab. Etanercept 
50 mg twice weekly was not considered to be cost effective.
Level of evidence Reference Design  Treatment Tolerability outcomes
1a Gottlieb et al. 2004b R, DB, PC, 12-week study
involving 1347 patients
ETN 25 mg, 50 mg
biw, or PLA
• ISR (low grade) was 14% for ETN vs 6% for PLA after 
12 weeks. The rate in the ETN group was lower than 
that seen in ETN studies in patients with RA (37%)
• 1.8% ETN- vs 2% of PLA-treated patients discontinued
treatment after AEs
• SAEs reported in 1.7% ETN- vs 1.2% in PLA-treated
patients
• Serious infections requiring hospitalization occurred 
in 0.3% of ETN- vs 1.2% of PLA-treated patients
2 Papp et al. 2005 R, DB, PC, 24-week 
study (OL phase during
weeks 13–24) involving
583 patients
ETN 25 mg or 50 mg
biw, or PLA for 
12 weeks. All patients
received ETN 25 mg
biw during OL phase
ISR (all mild or moderate) was the most commonly 
reported event:
• 16% of ETN- vs 6% of PLA-treated patients after 
12 weeks 
• 4% of ETN- vs 10% of PLA-treated patients after 
24 weeks
aAbstract.
AE, adverse event; biw, twice weekly; DB, double-blind; DLQI, Dermatology Life Quality Index; ETN, etanercept; ISR, injection site reaction; OL, open-label; PC, placebo-controlled; 
PLA, placebo; R, randomized; RA, rheumatoid arthritis; SAE, serious adverse event. 
Table 6 | Tolerability of etanercept in patients with psoriasis
Core Evidence 2007;2(1)A US study investigated how changes to copayments for
psoriasis treatments affect patients’ expenses (Simpson et al.
2006). Out-of-pocket expenses were estimated to be $US1800
for phototherapy and $US840 for etanercept, with corresponding
costs to managed care organizations of $US3008 and 
$US20300. Copayment structures are therefore favorable for
patients receiving etanercept, but less so for managed care plans. 
There is evidence from one meeting abstract that patients with
moderate to severe psoriasis who have failed methotrexate
therapy are likely to benefit from etanercept treatment in a
reasonably cost-effective manner (Nallamothu et al. 2004). The
study consisted of a computerized decision analytic model using
a Markov process to assess benefits (QALY) and costs ($US) for
the treatment strategies of methotrexate alone or methotrexate
followed by etanercept over 5 years. All cost estimates were
obtained from one center. The methotrexate strategy treatment
consisted of a maintenance dose of 15 mg/week if 20 mg/week
was successful during a 3-month induction phase. If the induction
phase was unsuccessful, then patients were started on etanercept
25 mg twice weekly for 3 months and continued on a maintenance
regimen of 25 mg weekly. However, as the recommended
approved maintenance dose is 50 mg weekly, the cost of this
treatment strategy may be underestimated (Anon. 2006). 
The analysis showed that methotrexate alone costs
approximately $US17 400 for a net benefit of 2.8 QALYs. 
In comparison, the methotrexate/etanercept strategy was 44%
more costly ($US25 000) but resulted in a greater benefit 
(3.1 QALYs). Thus, the ICER for the methotrexate/etanercept
strategy was $US25 000 per QALY (i.e. a cost difference of
$US7600 for a net benefit of 0.3 QALY). This value is sensitive to
estimates of the long-term efficacy and cost of etanercept
(Nallamothu et al. 2004). Therefore, although improved benefit
may be achieved with the methotrexate/etanercept strategy, there
are additional cost implications which may have to be evaluated
on a case-by-case basis. 
Resource utilization
Because of shortcomings of some of the standard established
treatments for psoriasis, the demand for newer, more effective,
more convenient and better-tolerated treatments is likely to be
high (Smith et al. 2005). The acquisition cost of etanercept of more
than $US12 000 per year is much higher than for other oral
systemic treatments for psoriasis (Lebwohl 2003). In contrast, the
average individual cost of phototherapy has recently been
estimated as €325.00 (range €57.20–972.40) (Langan et al. 2004).
Thus, it will be important to establish a rationale for developing a
long-term cost model to assess the use and associated
economics for the use of etanercept (and other targeted biologics)
for the treatment of psoriasis. Considerations for evaluating the
costs of these agents should include the ability to maintain 
off-treatment remissions or clearing, improvements in patients’
quality of life, and better safety and tolerability profiles (Rich 2004). 
At present comprehensive economic data on etanercept in
psoriasis are limited, and its long-term effect on the burden of the
disease is unknown. It will be important to determine in future
studies the drug’s effect on reductions in direct and indirect costs
of the disease. For example, successful treatment of severe
disease may result in significant reductions in visits to physicians,
length of hospital stay in some cases, and work days lost to the
disease or treatments. Until studies assess these resources,
costs, and outcomes, the overall effect of etanercept will be
difficult to determine. Whether the benefits gained from
etanercept justify its acquisition cost will be a matter for decision
makers in individual healthcare systems. 
Patient group/population
In the USA, etanercept is licensed for the treatment of adult patients
with chronic moderate to severe plaque psoriasis who are
candidates for systemic therapy or phototherapy. In contrast, UK
guidelines indicate that patients should have severe disease and
have either failed or be intolerant to established therapies to be
considered eligible for treatment (Smith et al. 2005). Patients treated
with etanercept should be withdrawn from therapy after 12 weeks 
if there has not been at least a 50% improvement in PASI (or body
surface area involvement) score from baseline (Smith et al. 2005).
NICE recommends the use of etanercept at a dose not exceeding
25 mg twice weekly in patients with a PASI ≥10 and DLQI >10,
whose psoriasis has failed to respond to, is intolerant to, or has a
contraindication to, systemic therapies (NICE 2006). Again,
treatment should be discontinued after 12 weeks if there has not
been a ≥75% improvement in PASI, or a ≥50% improvement in PASI
plus a 5-point reduction in DLQI. A European expert panel recently
recommended initiating treatment with 50 mg twice weekly, and
maintaining until remission for a maximum of 24 weeks; retreatment
is dependent on the physician’s assessment (Boehncke et al. 2006).
At present there is limited (level 5 only) evidence from case studies
that etanercept is effective in some other types of psoriasis.
Etanercept 25 mg twice weekly was effective in the treatment of
pustular psoriasis (Kamarashev et al. 2002) and recalcitrant
palmoplantar psoriasis unresponsive to other treatments,
including topical therapy and phototherapy (Weinberg 2003). 
Dosage, administration, and formulations
In the USA, etanercept is indicated for the treatment of adult
patients (18 years or older) with chronic moderate to severe
plaque psoriasis who are candidates for systemic therapy or
phototherapy. It is supplied in a single-use prefilled 1 mL syringe
as a sterile, preservative-free solution containing 50 mg/mL
etanercept, or as multiple-use 1 mL vial of etanercept 25 mg/mL
for subcutaneous injection.
In the US, the recommended starting dose of etanercept for adult
patients is 50 mg twice weekly (administered 3 or 4 days apart) for
3 months, followed by a reduction to a maintenance dose of 
50 mg per week. In the EU, the recommended is 25 mg twice
weekly, or 50 mg twice weekly for up to 12 weeks followed if
necessary by 25 mg twice weekly. Treatment should continue until
remission for up to 24 weeks, and should be discontinued if no
response has been achieved within 12 weeks. 
Etanercept | clinical impact review
© 2007 Core Medical Publishing Limited 6061
Etanercept | clinical impact review
Patients are encouraged to self-administer etanercept. The most
common locations for subcutaneous injections are the abdomen,
middle thigh, and the outer area of the upper arms. So that
injection site reactions are minimized, patients are instructed to
rotate the site for each injection. Areas where the skin is tender,
bruised, red, or hard or where there are scars or stretch marks
should be avoided (Anon. 2006).
Clinical value
There is good evidence from a number of large, good quality
clinical studies showing that treatment with etanercept for up to
24 weeks improved physician-assessed clinical outcomes when
compared with placebo. These outcomes were seen as soon as
two to four weeks from initiating treatment. More patients treated
with etanercept had improvements in their disease score (PASI)
and achieved clearance compared with placebo. On stopping
treatment in clinical studies the mean time to relapse was 
3 months, with a quarter of patients not experiencing relapse until
at least after 5 months. 
One of the most debilitating aspects of severe psoriasis is the
effect that it has on patients’ quality of life and mental and
physical function. There is good evidence that significant
improvements in these patient-oriented outcomes have been
achieved with etanercept in clinical studies. Improvements in
scores of both disease-specific (DLQI) and generic (SF-36)
instruments have been achieved. Limited evidence has also
emerged recently suggesting that etanercept can improve
symptoms associated with depression and fatigue, which are
often experienced in patients with psoriasis. 
There is limited evidence that etanercept can be used in combination
therapy. Although the combination of etanercept and methotrexate
has been used successfully for the treatment of rheumatoid arthritis
and psoriatic arthritis, phase III and IV studies in patients with
psoriasis with this and other combinations are still underway.
Experience with TNF inhibitors has raised some clinical concern
regarding risks of opportunistic infections and malignancy. Most
of the evidence related to the safety and tolerability of etanercept
has been gained from its long-term use in patients with
rheumatoid arthritis. In contrast, many fewer patients with
psoriasis have been exposed to the drug. However, the evidence
so far suggests that the safety profile in both patient populations
is similar. The most commonly experienced adverse event is an
injection site reaction which may occur in up to 20% of patients.
Typically such a reaction occurs within the first month of
treatment and spontaneously resolves. Experience with patients
with rheumatoid arthritis has shown that serious adverse effects
may be avoided or limited by following suitable screening
procedures and published guidelines when considering using
etanercept. Nevertheless, long-term monitoring will be required to
determine the potential for increased risk of infection and
malignancy in of TNF inhibitor-treated patients with psoriasis.
In conclusion, patients with moderate to severe psoriasis who are
candidates for systemic therapy or phototherapy now have the
option of effective and convenient treatment with etanercept.
Because of its higher acquisition cost compared with existing
systemic treatments, more economic studies and modeling will
be required to define its cost effectiveness in the disease. 
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